High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy

MeSH terms

• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Bipolar Disorder / etiology
• Boronic Acids / administration & dosage
• Boronic Acids / adverse effects
• Bortezomib
• Combined Modality Therapy
• Dose-Response Relationship, Drug
• Female
• Humans
• Induction Chemotherapy / adverse effects
• Induction Chemotherapy / methods*
• Kaplan-Meier Estimate
• Male
• Melphalan / administration & dosage
• Melphalan / adverse effects
• Middle Aged
• Multiple Myeloma / diagnosis
• Multiple Myeloma / therapy*
• Nausea / etiology
• Neutropenia / etiology
• Pyrazines / administration & dosage
• Pyrazines / adverse effects
• Remission Induction
• Stem Cell Transplantation / adverse effects
• Stem Cell Transplantation / methods*
• Transplantation Conditioning / adverse effects
• Transplantation Conditioning / methods*
• Transplantation, Autologous
• Treatment Outcome